Rayno Diagnostics and Tools-Awaiting Q1 Results

Many Rayno Diagnostics and Tools stocks have made new highs recently despite the sector being less frothy than biopharmaceuticals. These stocks are more pinned to financial results and dependent on a steady stream of new products. Important themes are genomics, molecular diagnostics, companion diagnostics and novel assays for infectious diseases like Flu and HCV. Recently we added Genomic Health (GHDX) a play in personalized medicine for cancer at $28.5 and Hologic (HOLX) at $21.60.

Hologic, a broad -based diagnostics and women’s health play has been a laggard and is selling off 4% today after the earnings release. Hologic results include the acquired GenProbe with Q2 revenues of $160.5M. The fiscal Q2 net loss was $51.1M or $0.19 per share. Revenue guidance was cut to $2.53B-2..55B from $2.61-$2.64B. Women’s health and imaging sales were mixed with Thin Prep Sales weak, so it appears that the GenProbe acquisition was the right move. We were a bit early into this stock but would still bet on a turnaround with the PE of 11.41 and a P/S of 2.56. This also has been a volatile stock with a lot of selling going on lately so we need to hold near the $20 level with some downside to $19.

Here is  a quick review of our portfolio:

Abaxis (ABAX) big winner,strong hold, buy on weakness, off top of $48.

Alere (ALR) reiterated buy at $19 after collapse of stock. Value play and turnaround now at $27.

Cardiovascular System (CSII) strong hold for Company focused in minimally invasive cardiovascular disease.

Cepheid (CPHD) top molecular diagnostics play, strong hold, despite valuation.

Exact Sciences (EXAS) long term play for molecular test for colon cancer.

Illumina (ILMN) big winner,up 11 pts since early April. Gotta be in this premier sequencing play, buy on weakness.

Neogen (NEOG) strong hold at new highs at $52. Niche products for food and animal safety.

Qiagen (QGEN) turnaround molecular diagnostic play has been disappointing.Hold is only for the patient.

Quidel (QDEL) big winner,off its highs near $25. Strong hold.

Response Genetics (RGDX) turnaround play.  A wait and see hold. Tightly held.

Sequenom (SQNM) a laggard, but pure play in prenatal genetic disorders.

ThermoFisher (TMO) huge winner up 33 pts. since July. Tools company acquiring major diagnostics companies. Still has value at PE 24 and P/S at 2.34.

For a complete summary of key financial metrics se our March 21 posting that summarizes 2012 Results.






%d bloggers like this: